Advanced Search
YANG Shuyan, ZHUANG Jinman, LIU Yuhang, ZHU Jinxiu, LIN Mengxin, HE Fei. Visual Analysis of Research on Lung Cancer Immunotherapy by Using CiteSpace[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 43-51. DOI: 10.3971/j.issn.1000-8578.2023.22.0495
Citation: YANG Shuyan, ZHUANG Jinman, LIU Yuhang, ZHU Jinxiu, LIN Mengxin, HE Fei. Visual Analysis of Research on Lung Cancer Immunotherapy by Using CiteSpace[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 43-51. DOI: 10.3971/j.issn.1000-8578.2023.22.0495

Visual Analysis of Research on Lung Cancer Immunotherapy by Using CiteSpace

Funding: 

Medical Innovation Project of Fujian Health Research Talents Training Project 2019-CX-33

Fujian Science and Technology Innovation Joint Fund Project 2019Y9022

More Information
  • Corresponding author:

    HE Fei, E-mail: i.fei.he@fjmu.edu.cn

  • Received Date: May 05, 2022
  • Revised Date: August 14, 2022
  • Available Online: January 12, 2024
  • Objective 

    To understand the current status of research on lung cancer immunotherapy to provide a reference for further investigation and future topic selection in this field.

    Methods 

    CiteSpace visualization analysis software was used to analyze 400 Chinese studies in CNKI and 5 001 English studies in the Web of Science database from 2005 to 2021, with "lung cancer" and "immunotherapy" as keywords. Keyword co-occurrence analysis was performed on 17 English studies of "Lung Cancer" "Immunotherapy" and "Single cell sequencing" in the Web of Science database.

    Results 

    "Non-small cell lung cancer" "immunosuppressants" "PD-L1" "dendritic cells" and "cytokine-induced killer cells" are current research hotspots in lung cancer immunotherapy. Monoclonal antibody drugs including nivolumab, pembrolizumab, atezolizumab, and durvalumab are hotspot drugs. Immunotherapy combined with chemotherapy as well as PD-L1 expression have become the focus of continuous research. The majority of studies on lung cancer immunotherapy are conducted in the United States, followed by China.

    Conclusion 

    Lung cancer immunotherapy has gradually become a research hot spot in China. In the future, in-depth research is needed to provide cutting-edge directions for lung cancer immunotherapy.

  • Competing interests: The authors declare that they have no competing interests.

  • [1]
    Sundar R, Soong R, Cho BC, et al. Immunotherapy in the treatment of non-small cell lung cancer[J]. Lung Cancer, 2014, 85(2): 101-109. doi: 10.1016/j.lungcan.2014.05.005
    [2]
    王丽萍. 肺癌免疫治疗现状及展望[J]. 中华实用诊断与治疗杂志, 2017, 31(2): 105-110. doi: 10.13507/j.issn.1674-3474.2017.02.001

    Wang LP. Current Situation and Prospect of Immunotherapy for Lung Cancer[J]. Zhonghua Shi Yong Zhen Duan Yu Zhi Liao Za Zhi, 2017, 31(2): 105-110. doi: 10.13507/j.issn.1674-3474.2017.02.001
    [3]
    Konala VM, Madhira BR, Ashra S, et al. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer[J]. Oncology, 2020, 98(11): 749-754. doi: 10.1159/000508516
    [4]
    Ko EC, Raben D, Formenti SC, et al. The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer[J]. Clin Cancer Res, 2018, 24(23): 5792-5806. doi: 10.1158/1078-0432.CCR-17-3620
    [5]
    Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018, 379(23): 2220-2229. doi: 10.1056/NEJMoa1809064
    [6]
    孙凤环, 陈健, 张鹏. 单细胞测序在肿瘤基因检测中的研究进展[J]. 同济大学学报(医学版), 2019, 40(1): 117-122. doi: 10.16118/j.1008-0392.2019.01.022

    Sun FH, Chen J, Zhang P. Research progress of single-cell sequencing in tumor gene detection[J]. Tongji Da Xue Xue Bao(Yi Xue Ban), 2019, 40(1): 117-122. doi: 10.16118/j.1008-0392.2019.01.022
    [7]
    Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639. doi: 10.1056/NEJMoa1507643
    [8]
    Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2015, 373(2): 123-135. doi: 10.1056/NEJMoa1504627
    [9]
    Reck M, Rodríguez-Abreu D, Robinson AG, et al. KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833. doi: 10.1056/NEJMoa1606774
    [10]
    Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2016, 387(10027): 1540-1550. doi: 10.1016/S0140-6736(15)01281-7
    [11]
    Garon EB, Rizvi NA, Hui R, et al. KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med, 2015, 372(21): 2018-2028. doi: 10.1056/NEJMoa1501824
    [12]
    Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015, 348(6230): 124-128. doi: 10.1126/science.aaa1348
    [13]
    Rittmeyer A, Barlesi F, Waterkamp D, et al. OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066): 255-265. doi: 10.1016/S0140-6736(16)32517-X
    [14]
    Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443-2454. doi: 10.1056/NEJMoa1200690
    [15]
    Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J]. Nature, 2014, 515(7528): 563-567. doi: 10.1038/nature14011
    [16]
    Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387(10030): 1837-1846. doi: 10.1016/S0140-6736(16)00587-0
    [17]
    马晓骉, 罗峰, 高永亮, 等. CIK细胞免疫疗法联合化疗治疗非小细胞肺癌的临床疗效[J]. 昆明医科大学学报, 2020, 41(12): 60-67. https://www.cnki.com.cn/Article/CJFDTOTAL-KMYX202012012.htm

    Ma XB, Luo F, Gao YL, et al. Clinical efficacy of CIK cell immunotherapy combined with chemotherapy in the treatment of non-small cell lung cancer[J]. Kunming Yi Ke Da Xue Xue Bao, 2020, 41(12): 60-67. https://www.cnki.com.cn/Article/CJFDTOTAL-KMYX202012012.htm
    [18]
    Wang L, Ma Q, Yao R, et al. Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer[J]. Int Immunopharmacol, 2020, 79: 106088. doi: 10.1016/j.intimp.2019.106088
    [19]
    程颖. 晚期非小细胞肺癌免疫治疗的研究进展[J]. 肿瘤防治研究, 2021, 48(8): 745-750. doi: 10.3971/j.issn.1000-8578.2021.21.0472

    Cheng Y. Research Progress of Immunotherapy for Advanced Non-small Cell Lung Cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2021, 48(8): 745-750. doi: 10.3971/j.issn.1000-8578.2021.21.0472
    [20]
    王奎, 张宏毅, 王泽权, 等. PD-1和PD-L1抑制剂治疗肺癌及其不良反应的研究现状及进展[J]. 中国医药科学, 2021, 11(3): 45-48. doi: 10.3969/j.issn.2095-0616.2021.03.012

    Wang K, Zhang HY, Wang ZQ, et al. Research status and progress of PD-1 and PD-L1 inhibitors in the treatment of lung cancer and its adverse reactions[J]. Zhongguo Yi Yao Ke Xue, 2021, 11(3): 45-48. doi: 10.3969/j.issn.2095-0616.2021.03.012
    [21]
    付烊, 朱波, 章必成. 晚期肺癌免疫治疗的现状与未来[J]. 医药导报, 2019, 38(8): 993-996. https://www.cnki.com.cn/Article/CJFDTOTAL-YYDB201908004.htm

    Fu Y, Zhu B, Zhang BC. Current status and future of immunotherapy for advanced lung cancer[J]. Yi Yao Dao Bao, 2019, 38(8): 993-996. https://www.cnki.com.cn/Article/CJFDTOTAL-YYDB201908004.htm
    [22]
    张秀梅, 翟运开, 赵杰, 等. 肺癌靶向治疗研究: 以文献计量学和可视化分析述的热点与趋势[J]. 现代肿瘤医学, 2020, 28(19): 3417-3427. doi: 10.3969/j.issn.1672-4992.2020.19.031

    Zhang XM, Zhai YK, Zhao J, et al. Lung cancer targeted therapy research: hotspots and trends described by bibliometrics and visual analysis[J]. Xian Dai Zhong Liu Yi Xue, 2020, 28(19): 3417-3427. doi: 10.3969/j.issn.1672-4992.2020.19.031
    [23]
    Ding Z, Li Q, Zhang R, et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer[J]. Signal Transduct Target Ther, 2021, 6(1): 26. doi: 10.1038/s41392-020-00448-5
    [24]
    周莹, 黄华艺. 单细胞测序技术及其在肿瘤研究和临床诊断中的应用[J]. 分子诊断与治疗杂志, 2017, 9(3): 147-153, 172. doi: 10.3969/j.issn.1674-6929.2017.03.001

    Zhou Y, Huang HY. Single-cell sequencing technology and its application in tumor research and clinical diagnosis[J]. Fen Zi Zhen Duan Yu Zhi Liao Za Zhi, 2017, 9(3): 147-153, 172. doi: 10.3969/j.issn.1674-6929.2017.03.001
    [25]
    Eberwine J, Sul JY, Bartfai T, et al. The promise of single -cell sequencing[J]. Nat Methods, 2014, 11(1): 25-27. doi: 10.1038/nmeth.2769
    [26]
    Borcoman E, Kanjanapan Y, Champiat S, et al. Novel patterns of response under immunotherapy[J]. Ann Oncol, 2019, 30(3): 385-396. doi: 10.1093/annonc/mdz003
    [27]
    Billan S, Kaidar-Person O, Gil Z. Treatment after progression in the era of immunotherapy[J]. Lancet Oncol, 2020, 21(10): e463-e476. doi: 10.1016/S1470-2045(20)30328-4
    [28]
    Mollaoglu G, Jones A, Wait SJ, et al. The lineage-defining transcription factors SOX2 and NKX2-1 determine lung cancer cell fate and shape the tumor immune microenvironment[J]. Immunity, 2018, 49(4): 764-779. e9. doi: 10.1016/j.immuni.2018.09.020
    [29]
    Rosenthal R, Cadieux EL, Salgado R, et al. Neoantigen-directed immune escape in lung cancer evolution[J]. Nature, 2019, 567(7749): 479-485. doi: 10.1038/s41586-019-1032-7
    [30]
    Xing XD, Yang F, Huang Q, et al. Decoding the multicellular ecosystem of lung adenocarcinoma manifested as pulmonary subsolid nodules by single-cell RNA sequencing[J]. Sci Adv, 2021, 7(5): eabd9738. doi: 10.1126/sciadv.abd9738
    [31]
    Guo X, Zhang Y, Zheng L, et al. Publisher Correction: Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing[J]. Nat Med, 2018, 24(10): 1628.
    [32]
    Ma KY, Schonnesen AA, Brock A, et al. Single-cell RNA sequencing of lung adenocarcinoma reveals heterogeneity of immune response-related genes[J]. JCI Insight, 2019, 4(4): e121387. doi: 10.1172/jci.insight.121387
    [33]
    Zhang F, Bai H, Gao R, et al. Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer[J]. Cancer Immunol Immun, 2020, 69(12): 2599-2611.
    [34]
    Chen Z, Yang X, Bi G, et al. Ligand-receptor interaction atlas within and between tumor cells and T cells in lung adenocarcinoma[J]. Int J Biol Sci, 2020, 16(12): 2205-2219. doi: 10.7150/ijbs.42080
  • Related Articles

    [1]FANG Yuhang, ZHANG Chuchu, SUI Bailu, WANG Yan, WANG Runxi, CHEN Yu, YUAN Xinhe, YANG Hongjun, ZHANG Ying. Visualization Analysis of Research Hotspots and Trends in Field of Tumor Therapy Based on CiteSpace and VOSviewer[J]. Cancer Research on Prevention and Treatment, 2025, 52(4): 297-304. DOI: 10.3971/j.issn.1000-8578.2025.24.0959
    [2]ZENG Xiaoxian, ZHANG Hong. Visualization Analysis of Research Hotspots and Trends in Treatment of Radioactive Iodine Refractory Differentiated Thyroid Carcinoma[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 156-164. DOI: 10.3971/j.issn.1000-8578.2025.24.0826
    [3]WANG Jinming, NAN Peng, ZHAO Yanmeidai, HAO Shulan. Visual Analysis of Hotspots and Trends in Inflammation-Related Research in Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(11): 926-936. DOI: 10.3971/j.issn.1000-8578.2024.24.0091
    [4]FANG Yuhang, XIE Yi, YANG Shuhan, LIU Suying, FANG Liyuan, WANG Yan, WANG Runxi, ZHANG Ying. Visualization Analysis of Research Hotspots of Breast Cancer Microenvironment Based on CiteSpace and VOSviewer[J]. Cancer Research on Prevention and Treatment, 2024, 51(6): 448-454. DOI: 10.3971/j.issn.1000-8578.2024.24.0004
    [5]GU Shanshan, XU Yun, WANG Jinghui. Current Status, Hot Spot Discovery and Integration Prospect of Cancer-related Fatigue Research at Home and Abroad Based on Bibliometric Visualization Map Analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(5): 418-426. DOI: 10.3971/j.issn.1000-8578.2022.21.0690
    [6]HONG Chen, PENG Xinyu, GUO Yin, WANG Jingsong. Research Progress of Exercise Intervention on Breast Cancer: A Visualization Analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(1): 32-39. DOI: 10.3971/j.issn.1000-8578.2022.21.0911
    [7]YANG Xi, CHU Yaojuan, CHEN Juanjuan, YANG Ting, LIU Chong, ZHANG Rui, DU Shuzhang. Visual Analysis and Focused Areas of Immunotherapy for Liver Cancer Based on Literature Data[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 963-969. DOI: 10.3971/j.issn.1000-8578.2021.21.0541
    [8]SUN Qiuyue, SUN Lichao, ZHANG Zhichun, PENG Liang, TIAN Gu. Trends in Research of Cancer Stem Cells: A Bibliometric Analysis Based on CiteSpace[J]. Cancer Research on Prevention and Treatment, 2021, 48(9): 839-845. DOI: 10.3971/j.issn.1000-8578.2021.21.0416
    [9]CHEN Dayang, ZONG Zengyan, XIONG Dan, WANG Mengmeng, DOU Xiaowen, JI Xiang, ZHANG Xiuming. Bibliometric Analysis of Nasopharyngeal Carcinoma Based on CiteSpace[J]. Cancer Research on Prevention and Treatment, 2020, 47(8): 596-599. DOI: 10.3971/j.issn.1000-8578.2020.19.1528
    [10]XIONG Senlin, ZHONG Xinyi, HUANG Qiuna, YANG Ying, ZHENG Weixin, QIU Hengjia. Visual Analysis of Chinese Literature on Cancer Screening in China Based on CiteSpace[J]. Cancer Research on Prevention and Treatment, 2020, 47(3): 198-203. DOI: 10.3971/j.issn.1000-8578.2020.19.0373
  • Cited by

    Periodical cited type(1)

    1. 王丹,赵启晟,李艳芳,焦妃,董旭,朱秀红,冯涛. 基于CiteSpace的集束化在抗感染方面应用研究可视化分析. 中国当代医药. 2023(30): 150-155 .

    Other cited types(1)

Catalog

    Figures(5)  /  Tables(6)

    Article views (1777) PDF downloads (684) Cited by(2)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return